David R Sierra

US Patent:

20070202186, Aug 30, 2007

Filed:

Feb 21, 2007

Appl. No.:

11/709941

Inventors:

Ronald Yamamoto - San Francisco CA, US
Stanley Conston - San Carlos CA, US
David Sierra - Aptos CA, US

Assignee:

iScience Interventional Corporation - Menlo Park CA

International Classification:

A61K 38/39
A61K 31/728
A61K 31/722
A61K 31/737
A61K 31/718
A61K 31/717
A61K 9/50

US Classification:

424490000, 514054000, 514012000, 514055000, 514057000, 514060000, 424078380

Abstract:

Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

US Patent:

20120136322, May 31, 2012

Filed:

Jun 1, 2011

Appl. No.:

13/151001

Inventors:

Yair Alster - Palo Alto CA, US
Cary J. Reich - Los Gatos CA, US
Stephen Boyd - Murrieta CA, US
David Sierra - Aptos CA, US
Jose D. Alejandro - Sunnyvale CA, US
K. Angela Macfarlane - Menlo Park CA, US
Douglas Sutton - Pacifica CA, US

Assignee:

ForSight Labs, LLC - Menlo Park CA

International Classification:

A61F 9/00
A61M 35/00

US Classification:

604290, 604302

Abstract:

A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

US Patent:

20130144128, Jun 6, 2013

Filed:

Sep 14, 2012

Appl. No.:

13/618052

Inventors:

Yair Alster - Menlo Park CA, US
Cary J. Reich - Menlo Park CA, US
K. Angela MacFarlane - Menlo Park CA, US
Janelle Chang - Menlo Park CA, US
Stephen Boyd - Menlo Park CA, US
David Sierra - Menlo Park CA, US
Jose D. Alejandro - Menlo Park CA, US
Douglas Sutton - Menlo Park CA, US

International Classification:

A61B 17/00

US Classification:

600236

Abstract:

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

US Patent:

20130216623, Aug 22, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/842218

Inventors:

Stanley R. Conston - San Carlos CA, US
David Sierra - Aptos CA, US

Assignee:

ISCIENCE INTERVENTIONAL CORPORATION - Menlo Park CA

International Classification:

A61K 9/00

US Classification:

424490, 514772, 424400, 514777, 514774, 5147726, 514779, 514778, 514781, 5147725, 514169, 514171

Abstract:

Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

US Patent:

20130245600, Sep 19, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/842288

Inventors:

Stanley R. Conston - San Carlos CA, US
David Sierra - Aptos CA, US

Assignee:

ISCIENCE INTERVENTIONAL CORPORATION - Menlo Park CA

International Classification:

A61F 9/00

US Classification:

604506

Abstract:

Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

US Patent:

59680180, Oct 19, 1999

Filed:

Oct 30, 1996

Appl. No.:

8/741233

Inventors:

Abigail Freeman - Fremont CA
Gerald G. Fuller - Palo Alto CA
David H. Sierra - Atherton CA
Stanley R. Conston - San Carlos CA
Alan S. Michaels - Chestnut Hill MA

Assignee:

Cohesion Corporation - Palo Alto CA

International Classification:

A61M 3700

US Classification:

604191

Abstract:

A fluid separation device and in-line orifice mixer system is disclosed. The fluid separation device utilizes a syringe, which is used for obtaining a fluid sample such as blood, in a centrifugation device, and further utilizes the syringe as a source of a separated fluid portion for storage and transfer for subsequent applications. The syringe containing the separated portion source and a second syringe containing a second source are connected to the in-line orifice mixer device. The mixer device comprises a plurality of orifice walls each providing an orifice non-aligned with adjacent orifices to homogeneously mix the plurality of components. The mixer device may further comprise an exit orifice wall with one or more orifices for discharge of the homogeneous mixture.

US Patent:

62807277, Aug 28, 2001

Filed:

Nov 9, 1999

Appl. No.:

9/436903

Inventors:

Jeffrey J. Prior - Redwood City CA
Donald G. Wallace - Menlo Park CA
David H. Sierra - Atherton CA
Frank A. DeLustro - Belmont CA

Assignee:

Cohesion Technologies, Inc. - Palo Alto CA

International Classification:

A61K 3800

US Classification:

424 9463

Abstract:

The present invention relates to thrombin-containing hemostatic compositions, their preparation and use. In particular, it relates to hemostatic compositions comprising stabilized thrombin and microfibrillar collagen in an aqueous medium. In a preferred embodiment of the present invention, the compositions are used in a kit comprising two different components, one of which is autologous patient's plasma as the source of fibrinogen, and the other of which is the thrombin-containing composition which also contains microfibrillar collagen.

US Patent:

62773941, Aug 21, 2001

Filed:

Jun 16, 2000

Appl. No.:

9/596183

Inventors:

David H. Sierra - Atherton CA

Assignee:

Cohesion Technologies, Inc. - Palo Alto CA

International Classification:

A61F 200

US Classification:

424426

Abstract:

The current invention is a biomedical implant comprising a biomedical matrix material and a biodegradable porosifying agent. As the porosifying agent degrades in situ, an implant with an inter-connecting network is formed. The resultant mechanically stable implant allows for tissue and fluid influx into the matrix. The invention is also directed to a method for repair of mammalian tissue using the above-described implant.